Quarterly Report • May 8, 2012
Quarterly Report
Open in ViewerOpens in native device viewer
(Figures in brackets refer to the same period of last year)
"The highlight of the quarter was naturally the new agreement we signed with Nestlé in February, which is of great strategic importance to BioGaia leading to an enhanced and extended collaboration. The agreement also creates an opportunity for us to let Nestlé market our products under the BioGaia brand in some of the larger markets." says Peter Rothschild, President of BioGaia.
A telephone conference on the interim report will be held today at 10:00 a.m. by President Peter Rothschild and CFO Margareta Hagman. To participate in the conference, please see BioGaia's website for telephone numbers http://www.biogaia.com/investors/agenda.
BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 8 May 2012, 8:00 a.m. CET.
Figures in brackets refer to the same period of last year.
The Board of Directors and the President of BioGaia AB (publ.) hereby present the interim report for the period from 1 January to 31 March 2012. A brief description of the company's operations is provided on page 13.
The highlight of the quarter was naturally the new agreement we signed with Nestlé in February, which is of great strategic importance to BioGaia leading to an enhanced and extended collaboration. This could be in both infant nutrition and other nutrition categories. The amount we have received as payment for the license in the infant formula area is substantial and will enable us to continue developing both our brand and innovative new products, whilst at the same time allowing the Board to propose generous dividends. The agreement also creates an opportunity for us to let Nestlé market our products under the BioGaia brand in some of the larger markets.
The program of clinical studies we have pursued for many years has continued to produce significant results. An important study on diarrhoea in children in Indonesia was published during the period, showing significant effects of Lactobacillus reuteri. One key aspect of the study, which was conducted by an independent institute, is that it also tested another probiotic strain belonging to a competitor, which showed no effects. These results clearly demonstrate that different probiotic strains behave differently, which means that studies on one strain cannot be used to market another. This is a message we have communicated to doctors and other healthcare professionals for several years.
Sales for the quarter grew by 12%, excluding the license revenue from Nestlé. The expected drop in sales of component products in 2012 as a consequence of the agreement with Nestlé is something we have mentioned earlier. However, this did not occur in the first quarter. Sales of finished consumer products rose by 2% during the quarter, which is lower than the increase in the first quarter of 2011. This is partly explained by large deliveries made at the end of December, after which several distributors did not order products for delivery during the quarter. As previously pointed out, a quarter is a short period of time and fluctuations can arise through the timing of deliveries before or after the quarterly shift. I therefore wish to emphasise the importance of looking at rolling 12-month sales to obtain a more accurate picture of our business development. Over the past 12-month period, our sales improved by 31%.
BioGaia's leading products in the finished consumer products category, drops and tablets, are currently sold in some 50 countries. Furthermore, we have agreements covering an additional 20 or so countries where we are in the process of registering our products. Launches will take place as soon as registration is completed. We are continuing to widen our geographic spread but for obvious reasons cannot expect to add a large number of new countries, although a few major markets remain. The focus is instead on reviewing our existing distribution agreements and expanding our distributors' portfolios with our new products. This means that we will replace our distributors in a number of markets, which will lead to a temporary decrease in our growth rate for a short period of time while the changes are carried out. Because changes will be made only where we sell
products under the BioGaia brand, the transfer will be simpler than would otherwise be the case. Some slowing down of sales was already noted during the quarter in connection with ongoing negotiations for the termination of existing distribution agreements and the start of new ones. However, I am convinced that the changes we are making will contribute to faster growth in a number of markets. Changes have already been done in Spain and Sweden and will take place in many more countries during the current year, which will leave us even better positioned for sustained good growth.
Consolidated net sales reached SEK 434.3 million (69.9). This figure includes license revenue from Nestlé (see below) of SEK 356 million that is regarded as nonrecurring revenue. All expenses related to the license have been taken as incurred. Excluding non-recurring revenue from Nestlé, net sales amounted to SEK 78.3 million (69.9), an increase of SEK 8.4 million (12%) compared to the first quarter of 2011. For the past 12 month period, sales were up by 31% over the same period of last year.
Sales of finished consumer products rose by SEK 1.2 million (2%) to SEK 54.8 million. The increase is smaller than the increase in the first quarter in 2011, partly due to large deliveries made at the end of 2011. Sales for the past 12 month period, which eliminates the effect of sales before or after the quarterly shift, show growth of 27% in this segment. Sales of finished consumer products rose in Asia and the USA, but declined in Europe and the rest of the world during the quarter compared to the same period of last year. The increase in Asia is mainly explained by higher sales in Japan. The decrease in Europe is due primarily to the large deliveries made in the fourth quarter of 2011 but also to the ongoing negotiations regarding change of distributors in a number of countries.
Sales of component products improved by SEK 363.1 million. Excluding non-recurring revenue from Nestlé, sales were up by SEK 7.1 million (45%) compared to the same period of last year. This is mainly due to a large delivery to Nestlé at the beginning of the year. Sales of component products rose in Europe but fell in Asia. The decrease in Asia is explained by the fact that the figures for the previous year include income from the termination agreement with Yili in China.
Sales of component products for the past 12-month period (excluding non-recurring revenue from Nestlé) grew by 40 per cent.
Sales in Europe improved by SEK 361.8 million. Excluding non-recurring revenue from Nestlé, sales increased by SEK 5.8 million (11%), mainly as a result of large deliveries to Nestlé. Final sales of Nestlé's products also take place outside Europe. For the past 12-month period, sales in Europe were up by 27 per cent (excluding non-recurring revenue).
Sales in Asia fell by SEK 0.4 million (4%). Sales of finished consumer products rose in Asia, but due to the fact that the first quarter of 2011 included income from the termination agreement with Yili in China, total sales in Asia declined for the period. For the past 12-month period, sales in Asia grew by 46%.
Sales in the USA and Canada strengthened by SEK 4.1 million (342%) as a result of increased sales of finished consumer products in the USA (mainly owing to Fleet's launch of strawberry-flavoured tablets) and higher sales in Canada. For the past 12-month period, sales in USA and Canada were up by 104%.
Sales in the rest of the world fell by SEK 1.0 million (17%), which is entirely attributable to temporary variations in deliveries. For the past 12-month period, sales improved by 11%.
Of total finished consumer products, 45% (40) were sold under the BioGaia brand. Including so-called co-branding, the percentage was 50% (48).
Gross profit amounted to SEK 411.5 million (48.5). Excluding non-recurring revenue from Nestlé, gross profit was SEK 55.5 million (48.5), which is an improvement of SEK 7.0 million (14%) compared to the same period of last year. Gross margin (excluding non-recurring revenue) rose from 69% to 71%. This is partly attributable to increased sales in Japan, where the margins are higher.
Selling expenses amounted to SEK 17.7 million (14.1), which is equal to 23% (20) of net sales (excluding nonrecurring revenue). The increase of SEK 3.6 million (26%) is mainly attributable to increased personnel expenses and marketing activities, as well as higher costs in Japan resulting partly from exchange rate fluctuations. For the past 12-month period, selling expenses rose by 14%.
Administrative expenses totalled SEK 3.2 million (2.8), which is equal to 4% (4) of net sales (excluding nonrecurring revenue). The increase of SEK 0.4 million (14%) is explained primarily by higher personnel expenses. Administrative expenses for the past 12 month period rose by 33%, mainly due to the consolidation of TwoPac as of 1 January 2011.
R&D expenses amounted to SEK 8.4 million (8.0), which is equal to 11% (11) of net sales (excluding non-recurring revenue).
The amortisation component of R&D expenses was SEK 0.2 million (0.3). Investments in capitalised development expenses totalled SEK 0 million (0). For the past 12 month period, R&D expenses grew by 17%.
Other operating income/expenses refer to foreign exchange gains/losses on operating receivables and liabilities.
Operating profit was SEK 382.1 million (23.4). Excluding non-recurring revenue from Nestlé, Operating profit was SEK 26.1 million, which is SEK 2.7 million (12%) better than in the same period of last year.
Profit before tax was SEK 384.9 million (25.6). Excluding non-recurring revenue, profit before tax was SEK 28.9 million, which is an improvement of SEK 3.3 million (13%) over the same period of last year.
Net financial items include a foreign exchange gain of SEK 1.4 million (1.7) on forward exchange contracts in EUR. At 31 March 2012, the company had outstanding forward exchange contracts for EUR 11.6 million at an average exchange rate of SEK 9.25. Forward exchange contracts amounting to EUR 6.4 million will mature for payment in
2012, EUR 4.8 million in 2013 and the remaining EUR 0.3 million in 2014. The actual exchange gain/loss depends on the exchange rate on the maturity date of the contracts. If the EUR rate on the maturity date is lower/higher than that at 31 March 2012 (8.85), an exchange gain/loss will be recognised in the future.
Profit after tax was SEK 283.2 million (18.5). Excluding non-recurring revenue from Nestlé, profit after tax was SEK 20.8 million, which represents an increase of SEK 2.3 million (16%) over the same period of last year. The tax rate for the Group was 28% (28). The Group pays tax on profits in the Swedish companies. The loss in Japan is not deductible against the Swedish profits. Loss carryforwards in the Japanese subsidiary at 31 March 2012 amounted to SEK 63.7 million. The deferred tax asset for these has not been recognised, since a sustainable profit level has not yet been shown in the Japanese subsidiary.
Earnings per share amounted to SEK 16.37 (1.04). Excluding non-recurring revenue, earnings per share were SEK 1.18.
The Group's cash and cash equivalents at 31 March 2012 totalled SEK 529.9 million (148.5).
Cash flow amounted to SEK 358.7 million (1.9). Excluding non-recurring revenue, cash flow was SEK 2.7 million.
The period's cash flow includes investments in property, plant and equipment of SEK 9.8 million (1.1), of which SEK 9.0 million refers to TwoPac.
Consolidated equity amounted to SEK 512.9 million (202.7) and the equity/assets ratio was 80% (85).
In connection with the year-end report and Annual Report, the Board proposed a dividend of SEK 4 per share. After the signing of the new agreement with Nestlé, the Board decided to propose an additional extraordinary dividend of SEK 2 per share. The total proposed dividend to be approved by the 2012 is thus SEK 6 per share.
Investments in property, plant and equipment amounted to SEK 9.8 (1.1) million, of which SEK 9.0 million (1.0) refers to TwoPac AB.
Net sales in the Japanese subsidiary were reported at SEK 3.7 million (2.1). Operating profit amounted to SEK -0.6 million (-1.4).
TwoPac is owned 50 per cent by BioGaia AB and 50 per cent by TwoPac's management. Since 1 January 2011 TwoPac AB is consolidated in the BioGaia group. Net sales in TwoPac were reported at SEK 6.3 million (5.0). Operating profit amounted to SEK 1.5 million (1.3). The profit after tax amounted to SEK 0.9 million (1.3). Construction of the new production facility in Eslöv is somewhat behind schedule and the facility is expected to be completed and taken into operation in the summer of 2012.
Net sales in the Parent Company are reported at SEK 431.2 million (68.7) and profit before tax was SEK 384.4 million (23.5). Profit after tax was SEK 283.1 million (16.4). Cash flow in the Parent Company Totalled SEK 362.3 million (-7.1).
Launches in the first quarter of 2012
| Distributor/licensee | Product | Country |
|---|---|---|
| Cube Pharmaceuticals | Oral rehydration solution (ORS) |
Greece |
| Fleet Laboratories | Digestive health tablets with strawberry flavour |
USA |
| Nestlé | Infant formula with Lactobacillus reuteri Protectis |
Bangladesh, Burma, Cambodia, the Caribbean, Laos and Singapore |
| Recalcine | Digestive health tablets and drops |
Bolivia |
Since 2008, BioGaia and Nestlé have collaborated in the field of infant nutrition products. After the signing of several new agreements in mid-February 2012, the parties have further extended this collaboration.
The agreements include the entry by Nestlé into a perpetual licence to use BioGaia's patented Lactobacillus reuteri in infant nutrition products for EUR 50.8 million. The initial payment of EUR 40 million (SEK 356 million) was made and recognised in the first quarter of 2012. Additional payments of EUR 10.8 million will be paid and recognised over a five-year period on the achievement of certain milestones.
The agreements are of significant strategic value for BioGaia, since they not only involve an extended collaboration with Nestlé but also provide greater financial freedom for BioGaia to further invest in its own brand, develop its own new products, conduct research on new indications and increase the distribution of BioGaia-branded products. The additional finances also give the Board scope to propose a generous dividend policy.
In addition, Nestlé has signed an option agreement with BioGaia to extend the use of Lactobacillus reuteri to other product areas.
Furthermore, Nestlé and BioGaia are working on several other projects, including the development of innovative products in the infant nutrition and other nutrition categories and the distribution of BioGaia-branded products in new markets. These further developments will be announced at an appropriate time closer to launch.
As a result of the up-front payments for the acquisition of the licence, BioGaia estimates that revenue from Nestlé during 2012, excluding the up-front payment, will be equal to around 50% of the value of sales during 2011, and will increase in 2013 to close to the 2011 level. From 2014 forward, sales are expected to exceed those in 2011.
A double-blind, placebo-controlled study of 494 children showed that supplementation of Lactobacillus reuteri Protectis significantly reduced episodes of diarrhoea. Lactobacillus reuteri Protectis was particularly effective in children with lower nutritional status. A probiotic strain from another company, which was also tested, was without effect.
The study was conducted independently from BioGaia and the results were announced in a press release by NIZO food research on 21 February 2012.
The study has been published in Journal of Pediatrics.
In mid-April BioGaia signed an agreement with United Laboratories Group for exclusive rights to sell BioGaia's probiotic drops and digestive health tablets in Taiwan. The products will be sold under the BioGaia brand and the launch is planned for 2012.
The number of employees in the Group at 31 March 2012 was 67 (60).
The Board has proposed that the 2012 AGM approve the implementation of a subscription warrant programme for the employees in the BioGaia Group involving the issue of 200,000 warrants. The warrants are proposed to be transferred at a market price calculated according to the Black & Scholes formula. If all 200,000 warrants are exercised for subscription to shares, the company's share capital will be increased by SEK 200,000, equal to a dilutive effect of around 1.14% on the share capital and approximately 0.83% on the total number of votes.
The business model previously used in Japan was found to be unsuccessful and the company changed in 2010 to the business model that is being used successfully in other markets. The Japanese subsidiary's sales have now picked up and are expected to increase continuously.
On the balance sheet date, assets in the Japanese subsidiary were reported at SEK 5.6 million in the Group. BioGaia's assessment is that there is no indication of impairment of these assets. In the Parent Company, all receivables and participations in the Japanese subsidiary have been written down to zero.
The shares in the subsidiary CapAble amount to a total of SEK 6.9 million in the Parent Company. So far CapAble has reported a loss. CapAble, which is 90.1% owned by BioGaia AB, was started in November 2008 to manufacture and sell
the patented LifeTop Cap. BioGaia made total conditional shareholder contributions of SEK 6 million to CapAble in 2009 and 2010. BioGaia's assessment is that CapAble will show good profitability, for which reason there was no indication of impairment on the balance sheet date.
For further information see the administration report and Notes 28 and 29 of the annual report for 2011.
The consolidated financial statements are presented in compliance with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) and the interpretations published by the IFRS Interpretations Committee (IFRIC) that have been endorsed by the European Commission for application in the EU.
This interim report has been prepared for the Group in accordance with IAS 34, Interim Financial Reporting, and the Annual Accounts Act, and for the Parent Company in accordance with the Annual Accounts Act.
Unless otherwise stated below, the Group and Parent Company have applied the same accounting and valuation standards as in the latest annual report.
The applied accounting policies correspond to those described in the annual report for 2011, aside from a number of minor amendments to existing standards and new interpretations that are effective as of 1 January 2012. These are not assessed to have any significant impact on the Group's or the Parent Company's profit, financial position or disclosures.
BioGaia's goal is to create strong value growth and a good return for the shareholders. This will be achieved through a greater emphasis on the BioGaia brand, increased sales to both existing and new customers and a controlled cost level.
The financial target is a sustainable operating margin (operating profit in relation to sales) of at least 30 per cent with continued strong growth and increased investments in research, product development and brand building.
BioGaia's dividend policy is to pay a shareholder dividend equal to 30 per cent of profit after tax.
Product launches are planned in a number of countries during the year. In view of the Company's strong portfolio consisting of an increased number of innovative products partly under the company's own brand, together with successful clinical trials and a growing distribution network covering a large share of the key markets, BioGaia's future outlook is bright.
| (Amounts in SEK 000s) | Jan-Mar | Jan-Mar | Jan-Dec | Apr 2011- | Apr 2010- |
|---|---|---|---|---|---|
| 2012 | 2011 | 2011 | Mar 2012 | Mar 2011 | |
| Net sales | 78,289 | 69,855 | 314,992 | 323,426 | 247,320 |
| License revenue | 356,004 | - | - | 356,004 | - |
| Cost of goods sold | -22,764 | -21,338 | -98,727 | -100,153 | -79,190 |
| Gross profit | 411,529 | 48,517 | 216,265 | 579,277 | 168,130 |
| Selling expenses | -17,677 | -14,140 | -66,079 | -69,616 | -61,260 |
| Administrative expenses | -3,153 | -2,813 | -13,014 | -13,354 | -10,104 |
| Research and development expenses | -8,414 | -7,968 | -34,317 | -34,763 | -29,737 |
| Other operating income/expenses | -204 | -211 | 304 | 311 | -2,218 |
| Share in profit/loss of associated company | - | - | - | - | 770 |
| Operating profit | 382,081 | 23,385 | 103,159 | 461,855 | 65,581 |
| Financial income | 2,855 | 2,202 | 5,792 | 6,445 | 11,627 |
| Financial expenses | -22 | -35 | -84 | -71 | -102 |
| Profit before tax | 384,914 | 25,552 | 108,867 | 468,229 | 77,106 |
| Tax expense | -101,719 | -7,071 | -29,345 | -123,993 | -23,657 |
| PROFIT FOR THE PERIOD | 283,195 | 18,481 | 79,522 | 344,236 | 53,449 |
| Other comprehensive income | |||||
| Gains/losses arising on translation of the financial | |||||
| statements of foreign operations | -696 | -478 | 712 | 494 | -458 |
| Comprehensive income for the period | 282,499 | 18,003 | 80,234 | 344,730 | 52,991 |
| Profit for the period attributable to: | |||||
| Owners of the Parent Company | 282,808 | 17,914 | 76,369 | 341,263 | 52,915 |
| Non-controlling interests | 387 | 567 | 3,153 | 2,973 | 534 |
| 283,195 | 18,481 | 79,522 | 344,236 | 53,449 | |
| Comprehensive income for the period attributable to: | |||||
| Owners of the Parent Company | 282,112 | 17,436 | 77,081 | 341,757 | 52,457 |
| Non-controlling interests | 387 | 567 | 3,153 | 2,973 | 534 |
| 282,499 | 18,003 | 80,234 | 344,730 | 52,991 | |
| Earnings per share | |||||
| Basic earnings per share (average number of shares), SEK | 16.37 | 1.04 | 4.42 | 19.76 | 3.07 |
| Diluted earnings per share, SEK | 16.37 | 1.04 | 4.42 | 19.76 | 3.06 |
| Number of shares, thousands | 17,271 | 17,271 | 17,271 | 17,271 | 17,271 |
| Average number of shares, thousands | 17,271 | 17,271 | 17,271 | 17,271 | 17,246 |
| Number of outstanding warrants, thousands | - | - | - | - | - |
| Number of outstanding warrants with a dilutive effect, thousands |
- | - | - | - | - |
| Number of shares after dilution, thousands | 17,271 | 17,271 | 17,271 | 17,271 | 17,271 |
| CONSOLIDATED STATEMENT OF FINANCIAL POSITION |
31 Mar | 31 Dec | 31 Mar |
|---|---|---|---|
| (Amounts in SEK 000s) | 2012 | 2011 | 2011 |
| ASSETS | |||
| Intangible assets | 177 | 264 | 933 |
| Property, plant and equipment | 32,256 | 24,158 | 13,926 |
| Other non-current receivables | 18 | 18 | 17 |
| Total non-current assets | 32,451 | 24,440 | 14,876 |
| Current assets excl. cash and cash equivalents | 79,316 | 83,858 | 74,409 |
| Cash and cash equivalents | 529,923 | 171,534 | 148,514 |
| Total current assets | 609,239 | 255,392 | 222,923 |
| TOTAL ASSETS | 641,690 | 279,832 | 237,799 |
| EQUITY AND LIABILITIES | |||
| Equity attributable to owners of the Parent Company | 511,876 | 229,764 | 204,662 |
| Non-controlling interests | 978 | 591 | -1,996 |
| Total equity | 512,854 | 230,355 | 202,666 |
| Provision for deferred tax | 185 | 185 | - |
| Interest-free current liabilities | 128,651 | 49,292 | 35,133 |
| TOTAL EQUITY AND LIABILITIES | |||
| 641,690 | 279,832 | 237,799 |
| CONSOLIDATED CASH FLOW STATEMENTS | Jan-Mar | Jan-Mar | Jan-Dec |
|---|---|---|---|
| (Amounts in SEK 000s) | 2012 | 2011 | 2011 |
| Operating activities | |||
| Operating profit | 382,081 | 23,385 | 103,159 |
| Depreciation/amortisation | 1,260 | 1,239 | 5,425 |
| Other non-cash items | 266 | 137 | 1,398 |
| 383,607 | 24,761 | 109,982 | |
| Gains/losses on realised forward exchange contracts | 285 | 1,935 | -164 |
| Paid tax | -17,246 | -18,375 | -35,768 |
| Interest received and paid | 1,394 | 514 | 3,189 |
| Cash flow from operating activities before changes in working capital |
368,040 | 8,835 | 77,239 |
| Changes in working capital | 462 | -8,402 | -4,447 |
| Cash flow from operating activities | 368,502 | 433 | 72,792 |
| Cash flow from investing activities | -9,821 | 1,488 | -13,567 |
| Cash flow from financing activities | - | - | -34,542 |
| Cash flow for the period | 358,681 | 1,921 | 24,683 |
| Cash and cash equivalents at beginning of period | 171,534 | 146,903 | 146,903 |
| Exchange difference in cash and cash equivalents | -292 | -310 | -52 |
| Cash and cash equivalents at end of period | 529,923 | 148,514 | 171,534 |
| (Amounts in SEK 000s) | Jan-Mar | Jan-Mar | Jan-Dec |
|---|---|---|---|
| 2012 | 2011 | 2011 | |
| At beginning of period | 230,355 | 187,323 | 187,323 |
| Dividends | - | - | -34,542 |
| Change in group structure | - | -2,660 | -2,660 |
| Comprehensive income for the period | 282,499 | 18,003 | 80,234 |
| At end of period | 512,854 | 202,666 | 230,355 |
(Amounts in SEK 000's)
| Revenue by Segment | Jan-March | Jan-March | Jan-Dec | April 2011- | April 2010- |
|---|---|---|---|---|---|
| 2012 | 2011 | 2011 | - March 2012 | - March 2011 | |
| Finished consumer products | 54 771 | 53 565 | 215 431 | 216 637 | 170 761 |
| Component products | 23 007 | 15 924 | 97 731 | 104 814 | 74 717 |
| Licence revenue (component products) 1) | 356 004 | - | - | 356 004 | - |
| Other products | 511 | 366 | 1 830 | 1 975 | 1 842 |
| 434 293 | 69 855 | 314 992 | 679 430 | 247 320 |
| Jan-March | Jan-March | Jan-Dec | April 2011- | April 2010- | |
|---|---|---|---|---|---|
| Gross profit by segment | 2012 | 2011 | 2011 | - March 2012 | - March 2011 |
| Finished consumer products | 39 464 | 36 681 | 154 015 | 156 798 | 114 092 |
| Component products | 15 677 | 11 474 | 60 523 | 64 726 | 52 353 |
| Licence revenue (component products) 1) | 356 004 | - | - | 356 004 | - |
| Other products | 384 | 363 | 1 727 | 1 748 | 1 685 |
| 411 529 | 48 518 | 216 265 | 579 276 | 168 130 |
1) The licence fee refers to the non-recurring revenue from Nestlé (please see above in the text). The licence fee should be included in the component products but is reported separately to allow a better comparison between the years.
| Jan-March | Jan-March | Jan-Dec | April 2011- | April 2010- | |
|---|---|---|---|---|---|
| Sales | 2012 | 2011 | 2011 | - March 2012 | - March 2011 |
| Europe | 59 549 | 53 793 | 234 505 | 240 261 | 189 360 |
| Licence revenue (Europe) 2) | 356 004 | - | - | 356 004 | - |
| USA and Canada | 5 303 | 1 228 | 17 816 | 21 891 | 10 702 |
| Asia | 8 394 | 8 784 | 37 117 | 36 727 | 25 146 |
| Rest of world | 5 043 | 6 050 | 25 554 | 24 547 | 22 112 |
| 434 293 | 69 855 | 314 992 | 679 430 | 247 320 |
2) The licence fee refers to the non-recurring revenue from Nestlé (please see above in the text). The licence fee should be included in Europe sales but is reported separately to allow a better comparison between the years.
| PARENT COMPANY INCOME STATEMENTS | Jan-Mar | Jan-Mar | Jan-Dec |
|---|---|---|---|
| (Amounts in SEK 000s) | 2012 | 2011 | 2011 |
| Net sales | 75,161 | 68,718 | 306,182 |
| License revenue | 356,004 | - | - |
| Cost of goods sold | -24,503 | -22,884 | -106,868 |
| Gross profit | 406,662 | 45,834 | 199,314 |
| Selling expenses | -13,246 | -10,548 | -49,406 |
| Administrative expenses | -2,874 | -2,565 | -11,607 |
| Research and development expenses | -8,433 | -7,856 | -34,283 |
| Other operating income | - | - | 304 |
| Other operating expenses | -204 | -211 | - |
| Operating profit | 381,905 | 24,654 | 104,322 |
| Impairment loss on receivable from subsidiary | -1,183 | -3,932 | -10,453 |
| Net financial items | 3,651 | 2,736 | 8,391 |
| Profit before tax | 384,373 | 23,458 | 102,260 |
| Tax expense | -101,290 | -7,068 | -29,781 |
| PROFIT FOR THE PERIOD | 283,083 | 16,390 | 72,479 |
| PARENT COMPANY BALANCE SHEETS | 31 Mar | 31 Dec | 31 Mar |
| 2012 | 2011 | 2011 | |
| ASSETS | |||
| Intangible assets | 177 | 264 | 933 |
| Property, plant and equipment | 2,138 | 2,068 | 2,771 |
| Shares in group companies | 21,160 | 21,160 | 21,110 |
| Non-current receivables from subsidiaries | 16,513 | 16,513 | 12,513 |
| Total non-current assets | 39,988 | 40,005 | 37,327 |
| Current assets excl. cash and cash equivalents | 69,787 | 73,643 | 68,147 |
| Cash and cash equivalents | 524,037 | 161,865 | 133,614 |
| Total current assets | 593,824 | 235,508 | 201,761 |
| TOTAL ASSETS | 633,812 | 275,513 | 239,088 |
| EQUITY AND LIABILITIES | |||
| Equity | 495,839 | 212,756 | 193,022 |
| Interest-free current liabilities | 137,973 | 62,757 | 46,066 |
| PARENT COMPANY CASH FLOW STATEMENTS | Jan-Mar | Jan-Mar | Jan-Dec |
|---|---|---|---|
| 2012 | 2011 | 2011 | |
| Operating activities | |||
| Operating profit | 381,905 | 24,654 | 104,322 |
| Depreciation/amortisation | 379 | 558 | 2,096 |
| Other non-cash items | 176 | 134 | 51 |
| Gain/losses on realised foreign exchange contracts | 285 | 1,935 | -164 |
| Paid tax | -17,246 | -18,375 | -35,769 |
| Interest received and paid | 1,545 | 567 | 3,582 |
| Cash flow from operating activities before changes in working capital | 367,044 | 9,473 | 74,118 |
| Changes in working capital | -4,333 | -6,972 | -2,686 |
| Cash flow from operating activities | 362,711 | 2,501 | 71,432 |
| Cash flow from investing activities | -363 | -9,594 | -15,813 |
| Cash flow from financing activities | - | - | -34,542 |
| Cash flow for the period | 362,348 | -7,093 | 21,077 |
| Cash and cash equivalents at beginning of period | 161,865 | 140,840 | 140,840 |
| Exchange difference in cash and cash equivalents | -176 | -133 | -52 |
| Cash and cash equivalents at end of period | 524,037 | 133,614 | 161,865 |
| (Amounts in SEK 000s) | Jan-Mar | Jan-Mar | Jan-Dec |
|---|---|---|---|
| 2012 | 2011 | 2011 | |
| At beginning of year | 212,756 | 176,632 | 176,632 |
| Dividends | - | - | -34,542 |
| Group contributions | - | - | -1,813 |
| Profit for the period | 283,083 | 16,390 | 72,479 |
| At end of period | 495,839 | 193,022 | 212,756 |
(Amounts in SEK 000s)
The Parent Company holds 100% of the shares in BioGaia Biologics Inc., USA , BioGaia Japan Inc., Tripac AB and Infant Baby AB.
The Parent Company holds 90.1% of the shares in CapAble AB.
The Parent Company holds 50% of the shares in TwoPac AB, which is reported as a group company.
| The following transactions have taken place with BioGaia Japan | Jan-Mar | Jan-Mar | Jan-Dec |
|---|---|---|---|
| 2012 | 2011 | 2011 | |
| Interest income | 656 | 506 | 2,244 |
| Loan provided | - | -2,448 | -4,451 |
| Purchase of goods | 527 | 978 | 3,759 |
Due to uncertainty about whether the receivable from BioGaia Japan will be recovered in the foreseeable future, a provision has been made for this amount.
| Jan-Mar | Jan-Mar | Jan-Dec | |
|---|---|---|---|
| 2012 | 2011 | 2011 | |
| Interest income | 149 | 43 | 487 |
| Loan provided | - | -7,091 | -11091 |
| Purchase of goods | -6,331 | -4,968 | -26,179 |
No significant transactions have taken place with other closely related companies.
| 31 Mar | 31 Mar | 31 Dec | |
|---|---|---|---|
| 2012 | 2011 | 2011 | |
| Non-current receivables from TwoPac AB (incl. subsidiary) | 15,491 | 11,491 | 15,491 |
| Current transactions with related parties | |||
| Current receivables from TwoPac AB | 149 | 43 | 349 |
| Current liabilities to TwoPac AB | -2,156 | -2,191 | -3,339 |
| -2,007 | -2,148 | -2,990 |
Annwall & Rothschild Investment AB holds 740,668 class A shares and 1,259,332 class B shares, which is equal to 11.6% of the share capital and 36.2% of the votes. Annwall & Rothschild Investment AB is owned by Peter Rothschild, President of BioGaia, and Jan Annwall, a member of the Board of the Parent Company. No transactions took place between BioGaia and Annwall & Rothschild Investment AB during the period.
| CONSOLIDATED KEY RATIOS 1) | Jan-Mar | Jan-Mar 2012 excl. non |
Jan-Mar |
|---|---|---|---|
| 2012 | recurring revenue |
2011 2) |
|
| Return on | |||
| - average equity | 76% | 9% | 9% |
| - average capital employed | 104% | 12% | 13% |
| Capital employed, SEK 000s | 513,039 | 250,664 | 202,666 |
| Number of shares, thousands | 17,271 | 17,271 | 17,271 |
| Average number of shares, thousands | 17,271 | 17,271 | 17,271 |
| Number of outstanding warrants, thousands | - | - | - |
| Average number of outstanding warrants with a dilutive effect, thousands |
- | - | - |
| Number of shares after dilution, thousands | 17,271 | 17,271 | 17,271 |
| Basic earnings per share, SEK | 16.37 | 1.18 | 1.04 |
| Diluted earnings per share, SEK | 16.37 | 1.18 | 1.04 |
| Basic equity per share, SEK | 29.64 | 14.45 | 11.85 |
| Diluted per equity per share, SEK | 29.64 | 14.45 | 11.85 |
| Equity/assets ratio | 80% | 88% | 85% |
| Operating margin | 88% | 33% | 33% |
| Profit margin | 89% | 37% | 37% |
| Average number of employees | 66 | 66 | 59 |
1) The definitions of key ratios correspond to those in the annual report.
2) Key ratios excluding non-recurring revenue from Nestlé (see above under "Financial performance in the first quarter of 2012").
| 8 May 2012 | 10:00 a.m. Teleconference with President Peter Rothschild and CFO Margareta Hagman. To participate in the conference, please see BioGaia's website for telephone numbers |
|---|---|
| http://www.biogaia.com/investors/agenda. | |
| 8 May 2012 | 4:00 p.m. Annual General Meeting at Citykonferensen Ingenjörshuset, Malmskillnadsgatan 46 in |
| Stockholm. | |
| 21 August 2012 | Interim report 1 January – 30 June 2012 |
| 23 October 2012 | Interim report 1 January – 30 September 2012 |
This interim report provides a true and fair picture of the business activities, financial position and results of operations of the Parent Company and the Group, and describes the significant risks and uncertainties to which the Parent Company and the Group companies are exposed.
Stockholm, 8 May 2012
David Dangoor Jan Annwall Stefan Elving
Thomas Flinck Inger Holmström Jörgen Thorball
Board member President
Board Chairman Board member Board member
Board member Board member Board member
Paula Zeilon Peter Rothschild
This interim report has not been examined by the company's independent auditor.
12 of 13
BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Lactobacillus reuteri (Reuteri) in combination with unique packaging solutions that make it possible to create probiotic products with a long shelf life.
The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of NASDAQ OMX Nordic Exchange Stockholm.
BioGaia has 67 employees, of whom 22 are based in Stockholm, 23 in Lund, 13 in Eslöv, two in Raleigh, USA, five in Hiroshima, Japan, and two in Shanghai, China.
BioGaia's revenue comes mainly from the sale of finished consumer products (digestive health tablets, drops, Oral Rehydration solution (ORS) and oral health products) to distributors, but also of revenue from the sale of component products such as Reuteri cultures, straws and caps.
The products are sold through nutrition, food, natural health and pharmaceutical companies in some 70 countries worldwide.
BioGaia holds patents for the use of Lactobacillus reuteri and certain packaging solutions in all major markets.
At the beginning of 2006 BioGaia launched its own consumer brand and today there are a number of distribution partners that sell finished products under the BioGaia brand in a large number of markets. One central part of BioGaia's strategy is to increase the share of sales consisting of BioGaia-branded products.
Some of BioGaia's distributors sell finished consumer products under their own brand names. For these products, the BioGaia brand is shown on the consumer package since BioGaia is both the manufacturer and licensor.
BioGaia's licensees add Reuteri culture to their products and sell these under their own brand names. On these products, the BioGaia brand is most often shown on the package as the licensor/patent holder.
Lactobacillus reuteri is one of the world's most well researched probiotics, especially in young children. To date, 92 clinical studies using BioGaia's human strains of Lactobacillus reuteri have been performed on around 7,700 individuals of all ages. The results have been published in 55 articles in scientific journals.
Studies have been performed on:
Publication of clinical trial results is a key success factor for BioGaia. The International Committee of Medical Journal Editors has initiated a policy requiring clinical investigators to deposit information about trial design into an accepted clinical trials registry before the onset of patient enrolment, and this has now become a prerequisite for publication of trial outcomes in major medical journals. ClinicalTrials.gov is a registry of clinical trials provided by the U.S. National Institutes of Health and BioGaia encourages all clinicians working with BioGaia products to register their trials on this site. Many of the trials are registered at an early stage, which means that some of the registered trials will not be performed as planned. Consequently, BioGaia takes no responsibility for ensuring that the registered trials reach completion or are successfully reported in the register or the scientific literature. When clinical trials results of significance to the company´s business do become available, BioGaia will report these through press releases.
2012-04-17 BioGaia signs exclusive distribution agreement for its probiotic drops and tablets in Taiwan
2012-04-04 Notice to attend the Annual General Meeting of BioGaia AB 2012-03-21 The Board of BioGaia proposes that the AGM approve an extraordinary dividend…
BioGaia AB Box 3242, SE-103 64 STOCKHOLM Street address: Kungsbroplan 3A, Stockholm Telephone: +46 8-555 293 00, Corp. Identity no. 556380-8723 www.biogaia.se For additional information contact: Peter Rothschild, President, BioGaia AB, telephone +46 8-555 293 00 Margareta Hagman, Executive Vice President, BioGaia AB, telephone +46 8-555 293 00
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.